Signal Boost 2026

Signal Boost 2026 Second week of January. Year of the Horse. Back in the saddle. As I point my GPS toward a familiar constellation of pursuits, here’s a topline look at what I’m watching and where I think the music business is headed in 2026. These aren’t predictions, they’re signals. More from Spin: Bruno Mars […]

What Contributes to Lifecore Biomedical’s (LFCR) Distinct Competitive Advantage?

Laughing Water Capital, an investment management company, released its fourth-quarter 2025 investor letter. In the quarter, Laughing Water Capital returned ~6.8%, bringing the full-year returns to ~3.9% net of fees and expenses. In comparison, the SP500TR and R2000 returned approximately 2.7% and 2.2%, respectively, in the quarter, and finished the year up by 17.9% and […]

Fermentation, Vol. 12, Pages 53: High Cell Density Fermentation Strategy for High-Level Soluble Expression of Glucagon-like Peptide-1 Analogue in Escherichia coli

Fermentation, Vol. 12, Pages 53: High Cell Density Fermentation Strategy for High-Level Soluble Expression of Glucagon-like Peptide-1 Analogue in Escherichia coli Fermentation doi: 10.3390/fermentation12010053 Authors: Sushmita R. Kumar Esha Shukla Gaurav Pandey Glucagon-like peptide-1 (GLP-1) is an incretin hormone and therapeutic agent for Type II diabetes mellitus. However, recombinant production in E. coli yields insufficient […]

The Biological Cost of Ozempic and Other GLP-1s

Get the Highest Quality Electrolyte https://euvexia.com . Losing belly fat is hard so you may wonder if a GLP-1 will work. The question isn’t whether GLP-1s drugs like Ozempic or Wegovy work. It’s whether the long-term biology works the same afterward. That distinction changes everything. 🔴Blood Work Course https://www.drekberg.shop/products/ultimate-blood-work-course-by-dr-sten-ekberg 🔴 MASTER YOUR HEALTH BY SUBSCRIBING […]

Glucagon-like peptide-1 medicines and cancer

Nature Cancer, Published online: 16 January 2026; doi:10.1038/s43018-025-01110-1 Yabut and Drucker discuss clinical and preclinical evidence about the potential roles of GLP-1 medicines on cancer incidence, development and therapy and speculate about their mechanism on cancer cells and the tumor microenvironment.

Weight-loss drugs may trigger the next restaurant crisis

Chad Finkelstein is a partner at the law firm of Dale & Lessmann LLP and chair of the firm’s franchising, licensing and distribution group. His clients include U.S. and Canadian franchisors. Survey quick-service restaurants right now and you’ll likely hear a version of the same story: Customers are still coming in, but they’re ordering less. […]